Published in Hepatitis Weekly, May 5th, 2003
NM283, a ribonucleoside analog being developed as an oral, once-daily treatment, appeared to be well tolerated and after 1 week of treatment reduced mean viral load by over 90% (1 log10) in a primate model of human chronic HCV infection.
Idenix also presented 24-week data from an ongoing phase IIb trial of telbivudine (LdT) for the treatment of hepatitis B virus (HBV) infection, further demonstrating its promising safety and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.